A new urine test to detect bladder cancer recurrence
Official title: Multiplex and multi-omic diagnostic test for bladder cancer recurrence
Funded at Early Is Good INC. · NIH-10918479 · Data updated 2026-11-12
This study is testing a new, easy urine test called BCDx that uses advanced technology to check for signs of bladder cancer without needing any invasive procedures, making it a friendlier option for patients who need to monitor their condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Early Is Good INC. NIH-funded |
| Lab location | 1 site (Muncie, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $821,797 |
| NIH project number | 1R44CA291290-01 |
| Project ID | NIH-10918479 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have been diagnosed with bladder cancer and are at risk for recurrence.
✕Less likely to help
Patients who have not been diagnosed with bladder cancer or those with other unrelated medical conditions may not benefit from this research.
What this research studies
This research focuses on developing a diagnostic test called BCDx that uses advanced nanotechnology to analyze urine samples for multiple biomarkers associated with bladder cancer. Unlike current methods that require invasive procedures, this test aims to provide a non-invasive and highly accurate way to monitor for cancer recurrence. By measuring various types of biological molecules, including proteins and RNA, the test seeks to improve the sensitivity and specificity of bladder cancer detection. This innovative approach could lead to earlier treatment interventions and better patient outcomes.
Why it matters
Potential benefit: If successful, this research could significantly reduce the need for invasive procedures and improve the accuracy of bladder cancer recurrence detection.
How similar studies have gone: Previous research has shown promise in using multi-omic approaches for cancer diagnostics, indicating potential success for this novel method.
Where this research is happening
-
Early Is Good INC.
Muncie, United States Active
Researchers
- Principal investigator: Liyanage, Thakshila — Early Is Good INC.
- Study coordinator: Liyanage, Thakshila
Related research
Other NIH-funded projects on the same topics.
-
Cruciferous vegetable program to lower bladder cancer recurrence
This project will see if a simple program to boost cruciferous vegetable intake can help people with early-stage (non-muscle invasive) bladder cancer lower the chance their cancer comes back or gets worse.
-
Multi-marker urine test to detect bladder cancer coming back
This project offers a urine test that looks for multiple cancer markers to help people treated for bladder cancer spot recurrence sooner.
-
Improving urine-based cancer cell cultures to monitor bladder cancer treatment and recurrence
This project tests whether collecting and handling urine the right way lets doctors grow bladder cancer cells from urine to help monitor treatment response and catch recurrence for people with bladder cancer.
-
Using cruciferous vegetables to help prevent bladder cancer from coming back
This study is looking at whether eating more cruciferous vegetables, like broccoli and kale, can help people with non-muscle invasive bladder cancer lower their chances of the cancer coming back or getting worse, and it’s designed for patients who want to try a natural way to support their health through diet.
-
Non-invasive urine tests for monitoring bladder cancer
This study is testing a new, easier way to check for bladder cancer using urine samples, which could help find out if the cancer comes back and how well treatments are working, making it more comfortable for patients than older methods.
-
Keloid recurrence study using multi-omics in diverse patients
A research effort will look at why keloids come back after surgery, especially in African American patients, using comprehensive molecular data from patient samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.